navigating ip markets · 2011-10-10 · medical device 3 – 5 % software 5 – 15 % semiconductors...

32
Navigating IP Markets MARQERA © 2011, All Rights Reserved

Upload: others

Post on 07-Aug-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Navigating IP Markets

MARQERA © 2011, All Rights Reserved

Page 2: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Technology Valuation Elena Canetti

VP Technology Transfer

Marqera LLC

Page 3: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Course Agenda

What is the right price: Value Vs. Price

Basic Methods of Valuation

1. Back Perspective

2. Around Perspective

3. Pieces Perspective

4. Down Perspective

5. Forward Perspective

6. Dice Perspective:

7, 8 and 9. Auction, Common Sense and Equity Perspective

Conclusions

Page 4: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

What is the right price: Value vs. Price

Value

An amount considered a suitable equivalent for something else.

Price

The sum of money or goods asked or given

for something.

Page 5: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Price vs. Value

Licensee’s Ceiling

©MARQERA, 2011, All Rights Reserved

Licensor’s Floor

Range of Negotiation

Page 6: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Valuation: a rational process

Without a valuation basis

With a valuation basis You negotiate the basis

You negotiate from emotion

Page 7: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

When is Technology Valued?

By litigators, Value established at a point in time.

Adversarial: the outcome is imposed judicially.

By deal makers, Value extracted over time. Prospectively

Retrospectively

Page 8: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Is that enough? How Much is my technology really worth?

Does the technology work in a production setting?

What product development activities will need to be further conducted?

Will there be commercially valuable patents to protect it from copycats?

How much is the end user willing to pay?

What regulatory requirements need to be fulfilled?

Page 9: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Prospective Valuation – The calculation of royalty

The calculation of royalty, depends on:

Technology Scope

Number and scope of patents

Know how

Patent age

Number of potential applications

Stage of technical development

Barriers to market entry

Exclusive or non exclusive rights

Page 10: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

The licensing perspective:

1. Back Perspective Costs

2. Around perspective Industry standards, comparables

3. Pieces perspective Ranking/rating

4. Down perspective Rules of thumb

5. Forward perspective Discounted cash flow

6. Dice Perspective Monte Carlo

7. Others Perspective Auction

8. No farther Perspective Common sense

9. Market Perspective Equity

Basic Methods of Valuation

Page 11: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Is cost to develop relevant? Development costs, patent costs?

1. Back Perspective

However it can be useful for: Development costs as a factor in determining value Modified replacement cost to calculate upfront

NO! it is a poor method for pricing.

Page 12: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Also known as the Cost Approach

Theoretical Background: Value is determined by the cost to replace or the cost to recreate

the IP.

Costs include: R&D, Materials, Equipment, Marketing, Advertising, Delayed Market

Entry.

Value of the IP: Fair market value of total investment to replace or recreate the IP.

©MARQERA, 2011, All Rights Reserved

NOTE: A licensee will not pay more for the IP than the amount for which the IP could be recreated. However, by licensing IP from others the licensee avoids development costs and minimizes risk

Page 13: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

2. Around Perspective: Comparables Approach

Constitutes of looking at sources of comparable transaction data

Internal database

Published surveys

Public announcements

Word of mouth

Litigation

Required disclosure

Page 14: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Royalty Rate Standards

Comments Royalty Product

1 % commodities, 2% processes 1 – 4 % Materials Processes

3 – 5 % Medical Device

5 – 15 % Software

Chip design 1 – 2 % Semiconductors

Composition of materials 8 – 10 % Pharmaceuticals

With clinical testing 12 – 20 %

New entity 4 – 5 % Diagnostics

New methods 2 – 4 %

Processes non exclusive 1 - 1.5 % Biotechnology

Processes exclusive 1 – 2 %

Adapted from Lita Nelsen, Director TLO of MIT

Page 15: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Licensing Executives Society – AU NZ Royalty chart

Avg. Median Max Min No. of Licenses

4.70% 4% 15.00% 1.00% 35 Automotive

4.70% 3.60% 25.00% 0.50% 72 Chemicals

5.20% 4% 15.00% 0.20% 68 Computers

5.50% 5% 17.00% 0.00% 90 Consumer Goods

4.30% 4% 15.00% 0.50% 132 Electronics

5.00% 5% 20.00% 0.50% 86 Energy & Environment

2.90% 2.80% 7.00% 0.30% 32 Food

5.80% 4.80% 77.00% 0.10% 280 Healthcare Products

11.70% 7.50% 40.00% 0.30% 47 Internet

5.20% 4.50% 25.00% 0.50% 84 Machines/Tools

10.60% 8% 50.00% 2.00% 19 Media & Entertainment

7.00% 5.10% 40.00% 0.10% 328 Pharma & Biotech

4.60% 3.20% 30.00% 0.00% 78 Semiconductors

10.50% 6.80% 70.00% 0.00% 119 Software

5.30% 4.70% 25.00% 0.40% 63 Telecom

Page 16: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Comparables Approach Sources

Most valuable tool for determining industry standards is the use of published agreements.

Published Data

• www.knowledgeexpress.com

• http://pharmalicensing.com/public/

Litigation

• Lexis/Nexis www.lexisnexis.com

SEC filing

• SEC EDGAR system www.sec.gov/edgar/

• EDGAR online: pro.edgar-online.com or www.tenkwizard

Databases

• www.recap.com (Deloitte)

• www.rDNA.com • http://www.recapip.c

om • http://www.recaprx.c

om • www.royaltysource.co

m • www.

techagreements.com • Disclosure

Information, Inc. www.thomson.com/financial/fi_partners.jsp

Page 17: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

3. Pieces Perspective: The Ranking Method

The ranking method:

Uses data from similar agreements

Uses a rating table to score the deal compared to known prices from comparable deals

Page 18: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

The Georgia Pacific Factors:

LICENSING OUT SCORE IMPORTANCE OF FACTOR

4.2 Nature of Protection

4.2 Utility over old methods

4.1 Scope of exclusivity

3.4 Licensee’s anticipated profits

3.4 Commercial Success

3.5 Territory Restrictions

3.7 Comparable License Rates

3.1 Duration of Protection

3.1 Licensor’s anticipated Profits

3.6 Commercial Relationship

2.1 Tag Along Sales

5 = MOST IMPORTANT, 1 = LESS IMPORTANT

Source: Stephen Degnan and Corwing Horton, “A Survey of Licensed Royalties”

Page 19: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Common 5 factor approach

WEIGHTED SCORE

WEIGHTING FACTOR

SCORE OF 1 TO 5

FACTORS

0.4 0.2 2 STAGE OF DEVELOPMENT

0.8 0.2 4 SCOPE OF IP PROTECTION

1 0.2 5 MARKET ATTRACTIVENESS (SIZE)

0.6 0.2 3 SUSTAINABILITY VS. COMPETITIVE TECHNOLOGIES

0.6 0.2 3 INDUSTRY PROFIT MARGINS

3.4 TOTAL WEIGHTED SCORE

Page 20: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Rules of Thumb

The 25% Rule: the Goldscheider Principle: the Licensor should receive 25% and the Licensee 75% of the pre-tax profits from a licensed product.

The second rule of thumb, converts roughly the 25% pre tax profit to 5% royalties

4. Down Perspective: the 25% Rule

Page 21: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

25% Rule

Meaning of the Rule:

The royalty in dollars should be 25% of the savings in dollars to the licensee by the use of the licensed technology

The royalty in percentages of net sale price should be 25% of the profit before taxes, enjoyed by the licensee by selling products based on the licensed technology

Page 22: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Discounted Cash Flow/Net Present Value

The method consists of determining future cash flows, then discounting the cash flows for the time over which those amounts are to be received and by the associated risk of receive such cash flows.

When all such cash flows have been discounted they can be added to determine the net present value (NPV)

5. Forward Perspective

Page 23: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Also Named the Income Approach

Theoretical Background: Value is determined by the economic benefit expected from use of

the IP.

Value of IP: Present value of the expected future income stream.

Key parameters: Amount of income stream

Duration of the income stream

Risk associated with the realization of the income

©MARQERA, 2011, All Rights Reserved

Note: Two well known methodologies: Excess Earnings and Relief from Royalties.

Page 24: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

METHOD OF CALCULATION OF NPV

xxx Sales

yyy Expenses

zzz Depreciation

rrr Royalties

EBT EARNINGS BEFORE TAX

ttt Taxes

EAT EARNING AFTER TAX

ddd Depreciation

iii Investments

www Working Capital

NCF NET CASH FLOW

NPV = Rn/(1+k)n Discount Cash by NPV

Embody risk in k Choose k.

Value: Risk plus timing and amount of future cash flows

Page 25: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Calculation of NPV

Each year cash flow (R in year n) is discounted by dividing each cash flow (R) by the term (1+k)n, where:

k - is the hurdle or discount rate

n – the year from the date in which the projected cash flow occurs

NPV = Rn/(1+k)n

Page 26: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Discount/Hurdle Rates for Start-Ups

Hurdle Risk Stage of Development

Pre-seed funding 100 % Research and Development

New business, seed funding, R&D stage 50 – 70 % Start Up

New business product ready for sale, no R&D required

40– 50% 1st Stage

New product and technology in existing business

30– 40% 2nd stage

New product, existing capabilities, known technology

25 – 30% Mezzanine/IPO

New product for existing manufacturing line and market

15% Low Risk

Page 27: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

6. Dice Perspective Montecarlo

Complex Mathematical modeling tools

A basic popular tool is the probabilistic model or Monte Carlo analysis

The tool works by replacing certain numbers in the calculation with a probabilistic value. The model is run hundreds of time to develop a distribution of outcomes

Page 28: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Plus and Minus of Monte Carlo P

LU

S • The model can be run over and over again

with changing assumptions • You get better understanding of the

assumptions and their economic impact • High risk technologies are not punished with

high hurdle rates.

MIN

US

• There is never a right answer • Requires appropriate software and user

experience

Page 29: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

About the other perspectives

6. Others Perspective: Auction

Technology auctions are rare, however patent auctions are not so rare

They are used for example in cases of bankruptcy or shut down

7. No farther Perspective:

Common sense

8. Market Perspective:

Equity – what is the value of a similar size, similar technology company in the stock exchange?

Page 30: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

IP Value in the Market

©MARQERA, 2011, All Rights Reserved

Page 31: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Conclusions

Valuating your technology is an excellent way to prepare for the negotiation of a successful deal (win win)

The Valuation of the technology is an essential part of the technology transfer process

With a valuation you negotiate with a sound economic basis and not from an emotional basis

Valuation of the technology is a way of determining the licensed technology value for the customer (licensee) and not only for the inventors (licensor)

Using more than one valuation method gives you a broader perspective, and accounts for a range of different factors

Page 32: Navigating IP Markets · 2011-10-10 · Medical Device 3 – 5 % Software 5 – 15 % Semiconductors 1 – 2 % Chip design Pharmaceuticals 8 – 10 % Composition of materials 12 –

Thank You!

Elena Canetti, VP Technology Transfer

Marqera LLC.

[email protected]

©, 2011, All Rights Reserved